DOUGLAS CRAWFORD

Douglas Crawford stands as a pivotal figure in the life science venture capital landscape, serving as a Managing Partner at Mission BioCapital. In this crucial role, he spearheads the firm's investment strategy, meticulously identifying and nurturing groundbreaking early-stage biotechnology and healthcare companies. His leadership is instrumental in guiding Mission BioCapital's mission to fund transformative scientific innovations that address significant unmet medical needs across various therapeutic areas.

Mission BioCapital, under Crawford's guidance, focuses intently on the nascent stages of company development. The firm's investment thesis centers on ventures with robust scientific foundations, often emerging from leading academic institutions. Douglas Crawford's expertise spans a broad spectrum of life science sectors, including novel therapeutics, advanced diagnostics, innovative medical devices, and cutting-edge digital health solutions. He is particularly adept at recognizing the potential in companies poised to revolutionize patient care and improve human health outcomes.

Crawford's distinguished career background provides a strong foundation for his success in venture capital. Holding a Ph.D. in Biochemistry from the University of California, Berkeley, and having completed postdoctoral research at the University of California, San Francisco, he possesses a deep understanding of scientific discovery and its translation into commercial applications. Prior to his current role, Douglas Crawford served as a Managing Director at the California Institute for Quantitative Biosciences (QB3), where he played a key role in fostering entrepreneurship and company formation within the academic ecosystem. He was also a co-founder of Mission Bay Capital, the predecessor to Mission BioCapital, further solidifying his long-standing commitment to early-stage life science investment.

His extensive experience includes not only evaluating scientific merit but also actively participating in the incubation and strategic development of portfolio companies. While specific individual "notable investments" are often attributed to the firm as a whole, Douglas Crawford has been deeply involved in shaping Mission BioCapital's impressive portfolio. This portfolio includes companies developing innovative treatments for oncology, neurological disorders, rare diseases, and infectious diseases, among others. His strategic insights and hands-on approach help guide these promising ventures from concept to clinical impact, driving both scientific progress and investor returns. Douglas Crawford's dedication to fostering innovation makes him a highly respected and influential leader in the biotechnology investment community.